Madenco Biosciences announces cosmeceuticals for treating acne scars, laser effects

Madenco Biosciences, a subsidiary of Quest PharmaTech, announced it has created a new line of cosmeceuticals targeting applications by dermatologist and medi-spas.

The SP-DERM line, based on Madenco’s proprietary SP-Technology platform, topically delivers molecules known as protein transduction-domain or cell penetrating peptides/proteins. The new products target recovery after intensive laser treatments, prolonging the effects of cosmetic procedures and minimizing the appearance of acne scars, according to a news release.

Patients with acne scars who were treated with SP-DERM Acne demonstrated both physician-assessed and patient-assessed improvements after 4 and 8 weeks of treatment in a preliminary pilot study, per the release.

“The result of this pilot study with SP-DERM Acne is encouraging and warrants further controlled clinical study,” Jaggi Rao, MD, FRCP, an Edmonton, Alberta, dermatologist and cosmetic surgeon who provided guidance in the development of the new products, stated in the release. “If proven, SP-DERM Acne could offer a unique effective therapeutic solution to millions of acne sufferers.”

“SP-DERM will fill a much-needed market niche as there is no current standard for post-procedural treatment or for acne scar treatment in dermatology clinics,” Madi Madiyalakan, PhD, CEO of Madenco/Quest, stated in the release. “With over $12 billion spent annually on cosmetic procedures in the U.S., there is a huge market potential for products like SP-Derm.”

Reference: www.questpharmatech.com, www.madencobio.com